| Trial ID: | L6701 |
| Source ID: | NCT00367978
|
| Associated Drug: |
Amlodipine/Benazepril
|
| Title: |
Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension
|
| Interventions: |
DRUG: Amlodipine/benazepril
|
| Outcome Measures: |
Primary: Time from baseline to the achievement of first treatment success (defined as achieving a blood pressure (BP) <130/80 mm Hg). The proportion and cumulative proportion of patients who achieved first treatment success were also determined. | Secondary: change from baseline in sitting diastolic BP at Week 24|change from baseline in sitting systolic BP at Week 24|change from baseline in urinary protein excretion at Week 24|change from baseline in HbA1c at Week 24|change from baseline in estimated glomerular filtration rate (EGFR) at Week 24
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
275
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2001-12
|
| Completion Date: |
2003-09
|
| Results First Posted: |
|
| Last Update Posted: |
2011-11-08
|
| Locations: |
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, 07936, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00367978
|
